Melanoma Shrinks With Injection After Anti-PD-1 Progression

(MedPage Today) -- Intratumoral injection of a toll-like receptor (TLR) agonist showed potential for reversing PD-(L)1 resistance in melanoma, a preliminary clinical trial showed.
A total of 23.5% of patients with metastatic melanoma responded...